Trials / Completed
CompletedNCT04973189
A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707 in Healthy Young Adult and Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous administration of SHR-1707 in healthy young adult and elderly subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1707 | A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults. |
| DRUG | Placebo | A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults. |
| DRUG | SHR-1707 | A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects. |
| DRUG | Placebo | A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects. |
Timeline
- Start date
- 2021-05-08
- Primary completion
- 2022-01-13
- Completion
- 2022-01-13
- First posted
- 2021-07-22
- Last updated
- 2023-05-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04973189. Inclusion in this directory is not an endorsement.